Physician profile
Bruce Daniel Finkel
NPI 1972562668
$6,394.84
in general payments reported to CMS, 2019-2025
32 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $847 · 2021: $978 · 2022: $1,010 · 2023: $851 · 2024: $747 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.35 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $892.31 | 2019-2025 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $566.78 | 2019-2025 | |
| Genzyme Corporation | $547.10 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $515.17 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $487.51 | 2020-2025 | Xembify |
| Pfizer INC. | $431.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $413.16 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $379.46 | 2020-2025 | Hizentra |
| Genentech USA, INC. | $347.69 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $285.36 | 2022-2025 | Glassia, Cuvitru, Takhzyro |
| Kaleo, INC. | $249.09 | 2019-2022 | |
| Pharming Healthcare, INC. | $221.19 | 2021-2025 | Ruconest |
| Glaxosmithkline, LLC. | $217.34 | 2019-2025 | Nucala |
| Optinose US, INC. | $153.11 | 2019-2025 | |
| Integra Lifesciences Corporation | $150.00 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87.99 | 2021-2025 | Tezspire, Actimmune |
| Hospira, INC. | $58.64 | 2022 | |
| Alk-Abello, INC | $52.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.40 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $39.28 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $35.69 | 2023-2024 | Ryaltris |
| Biocryst US Sales Co., LLC | $35.50 | 2021-2022 | |
| Gc Biopharma USA, INC. | $27.70 | 2024 | Alyglo |
| Abbvie INC. | $20.93 | 2024 | |
| Leo Pharma INC. | $20.40 | 2025 | Anzupgo |
| Galderma Laboratories, L.P. | $18.54 | 2025 | Nemluvio |
| Circassia INC. | $18.48 | 2019 | |
| Uswm, LLC | $17.86 | 2021 | |
| Horizon Therapeutics Plc | $17.29 | 2020 | |
| Dermavant Sciences, INC. | $16.87 | 2024 | Vtama |
| Phathom Pharmaceuticals, INC. | $15.18 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Finkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.